Tvardi Therapeutics (LTS:0HTC) Earnings Power Value (EPV): £1.98 (As of Mar26)


What is Tvardi Therapeutics Earnings Power Value (EPV)?

Tvardi Therapeutics LTS:0HTC 12 Earnings Power Value (EPV) is £1.98 as of Mar26. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

As of Mar26, Tvardi Therapeutics's earnings power value is £1.98. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.

Tvardi Therapeutics  (LTS:0HTC) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.

Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.

Tvardi Therapeutics Earnings Power Value (EPV) Related Terms

Tvardi Therapeutics Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Earnings Power Value (EPV) Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0HTC vs HOWL, TPST, XCUR: Earnings Power Value (EPV) Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Earnings Power Value (EPV) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Earnings Power Value (EPV) falls into.


Tvardi Therapeutics Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

What does a Earnings Power Value (EPV) of £1.98 mean?
Tvardi Therapeutics (LTS:0HTC) has a Earnings Power Value (EPV) of £1.98 as of Mar26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Earnings Power Value (EPV) too high?
Tvardi Therapeutics' current Earnings Power Value (EPV) is £1.98. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Earnings Power Value (EPV) compare to HOWL and TPST?
Tvardi Therapeutics' Earnings Power Value (EPV) of £1.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Earnings Power Value (EPV) is £1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Earnings Power Value (EPV) of £1.98. The current Earnings Power Value (EPV) is £1.98. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Earnings Power Value (EPV) is £1.98 as of Mar26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.